Jung-Chen Su

794 total citations
26 papers, 699 citations indexed

About

Jung-Chen Su is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Jung-Chen Su has authored 26 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Jung-Chen Su's work include Cytokine Signaling Pathways and Interactions (8 papers), Protein Tyrosine Phosphatases (7 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Jung-Chen Su is often cited by papers focused on Cytokine Signaling Pathways and Interactions (8 papers), Protein Tyrosine Phosphatases (7 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Jung-Chen Su collaborates with scholars based in Taiwan, China and United States. Jung-Chen Su's co-authors include Chung-Wai Shiau, Kuen‐Feng Chen, Chun‐Yu Liu, Long‐Sen Chang, Kuei-Li Lin, Shinne-Ren Lin, Ling‐Ming Tseng, Pei‐Yi Chu, Wei‐Tien Tai and Yeh-Long Chen and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Molecules.

In The Last Decade

Jung-Chen Su

26 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jung-Chen Su Taiwan 17 435 245 118 91 86 26 699
Huameng Li United States 15 417 1.0× 335 1.4× 143 1.2× 87 1.0× 39 0.5× 19 946
Ailian Xiong United States 11 264 0.6× 223 0.9× 95 0.8× 85 0.9× 61 0.7× 14 544
Marianna G. Yakubovskaya Russia 18 572 1.3× 143 0.6× 82 0.7× 74 0.8× 95 1.1× 83 863
Yulia Maxuitenko United States 16 479 1.1× 179 0.7× 53 0.4× 119 1.3× 63 0.7× 46 775
Łukasz Sędek Poland 16 306 0.7× 113 0.5× 114 1.0× 82 0.9× 32 0.4× 59 771
Hao Deng China 16 277 0.6× 162 0.7× 58 0.5× 108 1.2× 149 1.7× 71 635
Hareesh B. Nair United States 15 259 0.6× 224 0.9× 139 1.2× 80 0.9× 191 2.2× 48 800
Stéphane Vispé France 16 952 2.2× 243 1.0× 44 0.4× 139 1.5× 85 1.0× 23 1.1k
Ramachandran Rashmi United States 15 717 1.6× 136 0.6× 96 0.8× 169 1.9× 25 0.3× 18 1.0k

Countries citing papers authored by Jung-Chen Su

Since Specialization
Citations

This map shows the geographic impact of Jung-Chen Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jung-Chen Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jung-Chen Su more than expected).

Fields of papers citing papers by Jung-Chen Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jung-Chen Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jung-Chen Su. The network helps show where Jung-Chen Su may publish in the future.

Co-authorship network of co-authors of Jung-Chen Su

This figure shows the co-authorship network connecting the top 25 collaborators of Jung-Chen Su. A scholar is included among the top collaborators of Jung-Chen Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jung-Chen Su. Jung-Chen Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Tengteng, et al.. (2025). Advancing VB12 Production: Insights into Enhancing VB12 Titer in Ensifer adhaerens Casida A through ARTP Mutagenesis and Multiomics Analysis. ACS Synthetic Biology. 14(4). 1264–1276. 1 indexed citations
2.
3.
Xu, Chunyan, Haixia Gao, Qing Han, et al.. (2024). First report of Fusarium redolens causing root rot of Goji berry cv. ‘Ningqi‐7’ in China. Journal of Phytopathology. 172(2). 1 indexed citations
4.
Lin, Hsin-Hung, et al.. (2021). Large-scale data analysis for robotic yeast one-hybrid platforms and multi-disciplinary studies using GateMultiplex. BMC Biology. 19(1). 214–214. 1 indexed citations
5.
6.
Su, Jung-Chen, et al.. (2018). Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1. Journal of Enzyme Inhibition and Medicinal Chemistry. 33(1). 1248–1255. 13 indexed citations
7.
Liu, Chun‐Yu, Kuen‐Feng Chen, Pei‐Yi Chu, et al.. (2017). Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Journal of Molecular Medicine. 95(9). 965–975. 22 indexed citations
8.
Huang, Tzu‐Ting, Jung-Chen Su, Chun‐Yu Liu, Chung-Wai Shiau, & Kuen‐Feng Chen. (2017). Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. International Journal of Molecular Sciences. 18(6). 1234–1234. 45 indexed citations
9.
Su, Jung-Chen, Szu‐Hsien Wu, Wei‐Tien Tai, et al.. (2016). Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Scientific Reports. 6(1). 28888–28888. 50 indexed citations
10.
Huang, Yu‐Ting, Chang‐Shi Chen, Yi‐Wei Chen, et al.. (2015). In vitroandin vivoactivity of a novel sorafenib derivative SC5005 against MRSA. Journal of Antimicrobial Chemotherapy. 71(2). 449–459. 25 indexed citations
11.
Su, Jung-Chen, Jui-Wen Huang, Ping‐Yu Chen, et al.. (2015). Copper–obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma. Chemico-Biological Interactions. 228. 108–113. 6 indexed citations
12.
Su, Jung-Chen, Ping‐Hui Tseng, Wei‐Tien Tai, et al.. (2014). RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget. 5(13). 4909–4919. 25 indexed citations
13.
Chen, Kuen‐Feng, Jung-Chen Su, Chun‐Yu Liu, et al.. (2012). A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Letters. 321(1). 27–35. 44 indexed citations
14.
Chen, Kuen‐Feng, Jung-Chen Su, Chun‐Yu Liu, et al.. (2012). Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorganic & Medicinal Chemistry. 20(20). 6144–6153. 35 indexed citations
15.
16.
Lin, Kuei-Li, Jung-Chen Su, Chih-Hua Tseng, et al.. (2010). Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: Involvement of EGF receptor/PI3K/Akt signaling pathway. European Journal of Pharmacology. 636(1-3). 52–58. 30 indexed citations
17.
Lin, Kuei-Li, Jung-Chen Su, Chih-Hua Tseng, et al.. (2010). Naphtho[1,2-b]furan-4,5-dione disrupts Janus kinase-2 and induces apoptosis in breast cancer MDA-MB-231 cells. Toxicology in Vitro. 24(4). 1158–1167. 13 indexed citations
18.
Su, Jung-Chen, Kuei-Li Lin, Chih-Hua Tseng, et al.. (2009). Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. Life Sciences. 86(5-6). 207–213. 20 indexed citations
19.
Su, Jung-Chen, Kuei-Li Lin, Chih‐Ming Lu, et al.. (2009). Novel indoloquinoline derivative, IQDMA, induces G2/M phase arrest and apoptosis in A549 cells through JNK/p38 MAPK signaling activation. Life Sciences. 85(13-14). 505–516. 25 indexed citations
20.
Lin, Kuei-Li, Jung-Chen Su, Chih-Hua Tseng, et al.. (2009). Naphtho[1,2-b]furan-4,5-dione induces apoptosis and S-phase arrest of MDA-MB-231 cells through JNK and ERK signaling activation. Toxicology in Vitro. 24(1). 61–70. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huameng Li Breakdown of academic impact, for papers by Ailian Xiong Breakdown of academic impact, for papers by Marianna G. Yakubovskaya Breakdown of academic impact, for papers by Yulia Maxuitenko Breakdown of academic impact, for papers by Łukasz Sędek Breakdown of academic impact, for papers by Hao Deng Breakdown of academic impact, for papers by Hareesh B. Nair Breakdown of academic impact, for papers by Stéphane Vispé Breakdown of academic impact, for papers by Ramachandran Rashmi
Rankless by CCL
2026